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Abstract Venous thromboembolism (VTE) is a major
source of morbidity and mortality for both surgical and
medical hospitalised patients. Despite the availability of
guidelines, thromboprophylaxis continues to be underuti-
lised. This study aims to assess the effectiveness of an
electronic VTE risk assessment tool (elVis) on VTE pro-
phylaxis in hospitalised patients. A national, multicentre,
prospective clinical audit collected information on VTE
prophylaxis and risk factors for VTE in 2,400 hospitalised
patients (comprising of equal numbers of medical, surgical
and orthopaedic patients). After auditing the standard care
use of VTE prophylaxis in 1,200 consecutive patients (audit
1, A1), the elVis system was installed and a second audit
(A2) of VTE prophylaxis was performed in a further 1,200
patients. The use of the electronic VTE risk assessment tool
was low with 20.5% of patients assessed with elVis. The
intervention, elVis plus accompanying education, improved
the use VTE prophylaxis to guidelines by 5.0% amongst all
patients and by 10.7% amongst high risk patients (adjusted
odds ratio (AOR) 1.27 and 1.65 respectively). The use of
elVis in A2 varied between hospitals and specialties and
this resulted in marked heterogeneity. Despite this hetero-
geneity, patients assessed with elVis had 1.44 times higher
AOR of being treated to guidelines compared to those who
were not (P \ 0.05). The use of elVis accompanied by staff
education improved VTE prophylaxis, especially amongst
high risk patients. To optimise the effectiveness and support
enduring practice change electronic systems, such as el-
Vis, need to be completely integrated within the treatment
pathway.
Keywords Deep vein thrombosis  Venous
thromboembolism  Pulmonary embolism  Guideline
adherence  Prevention  Thromboprophylaxis
Introduction
Venous thromboembolism (VTE), which comprises of
pulmonary embolism (PE) and deep vein thrombosis
(DVT), is a major source of morbidity and mortality for
both surgical and medical hospitalised patients. It is the
most common preventable cause of hospital-related death
[1], yet despite the availability of clinical guidelines in
Australia [2, 3] and internationally [4, 5], thrombopro-
phylaxis continues to be underutilised [1, 6] and has been
identified as ‘‘the number one strategy to improve patient
safety in hospitals’’ [5].
In 2008, it is estimated that there were over 14,500 cases
of VTE and approximately 5,000 deaths due to VTE in
Australia. The estimated financial cost of VTE was in
excess of AU$1.7 billion, with 80% of these costs due to
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lost productivity as a result of premature death [7]. Western
Australian hospital morbidity data determined that in
1999–2001 the rate of VTE was 80 per 100,000 hospita-
lised patients with equal proportions arising from medical
and surgical admissions. Over half of secondary cases of
VTE occurred as readmissions within 3 months of the
original hospital admission [8]. Most hospitalised patients
have one or more risk factors for VTE [3]. Surgery is a well
established VTE risk factor and the use of thrombopro-
phylaxis is generally higher amongst surgical patients than
medically ill patients [9], however VTE cases in acute
hospital settings are equally attributable to medical and
surgical admissions [10]. In addition, 50–70% of symp-
tomatic events and 70–80% of fatal PEs occur in non-
surgical patients [5, 11–14].
The ENDORSE study has demonstrated that VTE pro-
phylaxis is suboptimal and that the use of thrombopro-
phylaxis in medically ill patients has particular scope for
improvement [9]. Amongst medically ill patients, prophy-
laxis appears to correlate with disease severity rather than
medical diagnosis, for example the recommended pro-
phylaxis was more likely to be instituted if the patient was
admitted into intensive care or required central venous
catheters, markers of severe disease [15].
There have been numerous efforts made to improve
VTE prophylaxis. Systematic reviews indicate that passive
methods, such as the dissemination of guidelines, is unli-
kely to translate into improved practice [16–20]. Factors
that appear to improve VTE prophylaxis are systems that
remind clinicians to assess the VTE risk status of patients,
and then assist clinicians prescribe the appropriate pro-
phylaxis for the risk classification. Studies which have used
electronic systems to facilitate these processes appear
promising in improving VTE prophylaxis [1, 21].
We report the results of a multicentre clinical audit
before and after an intervention, examining the effective-
ness of an electronic risk assessment system on VTE pro-
phylaxis in hospitalised patients. The primary objective
was to determine the effect on the rate of VTE prophylaxis
in hospitalised patients of an electronic risk assessment tool
that guides appropriate management according to guide-
lines or local protocols. Secondary objectives were to
assess the appropriateness of VTE prophylaxis in hospita-
lised medical, surgical and orthopaedic patients and to
describe the types of VTE prophylaxis prescribed.
Methods
A multicentre prospective audit was performed in 6 hos-
pitals across Australia. The audit collected information on
VTE prophylaxis and risk factors for VTE in 2,400 hos-
pitalised patients. The selection and use of VTE
prophylaxis was based on standard care and was not
determined by the audit protocol.
Participants in the audit were adult patients (aged C18
years) hospitalised for at least 24 h in a medical or surgical
ward. Patients were excluded from the study if they had
participated in a VTE study in the last 90 days, or if they
were admitted to the following hospital wards; intensive
care, coronary care, paediatrics, maternity, gynaecology, or
psychiatry. Individual patients could only be audited once,
if they were re-admitted to hospital, VTE prophylaxis was
not audited on subsequent admissions.
Each study site performed a baseline audit of 120 or 240
consecutive patients (comprising of equal numbers of
medical, surgical and orthopaedic patients) regarding VTE
risks, prophylaxis and bleeding risks. This data was
recorded on a data collection form, to reflect the conditions
present on admission or developed whilst in hospital,
regardless of the length of hospital stay. After completing
the first audit (A1), the electronic VTE risk assessment
system was installed by Core Medical Solutions into each
participating hospital. The electronic VTE risk assessment
system allowed VTE risk to be classified as high or not
high for each patient, based on local hospital guidelines,
and the system flagged any patient that had not had their
VTE risk assessed. Implementation of the electronic sys-
tem was accompanied by medical officer education on its
use and a general increase in awareness of VTE prophy-
laxis. After the electronic risk assessment tool was
embedded within the hospital, a second audit (A2) of VTE
risks and prophylaxis was conducted on an additional 120
or 240 consecutive patients. The second audit was com-
pleted as early as 5 months and no later than 10 months
after the first audit. The number of patients to be audited at
each hospital was based on the hospital’s capacity to
complete the audit within the study timeframe. Four hos-
pitals recruited 240 patients in each audit cycle and two
hospitals recruited 120 patients per cycle.
This audit was conducted in accordance with the Dec-
laration of Helsinki [22] and written approval was obtained
from the relevant Human Research Ethics Committee at
each study site. Patient consent was not obtained as the
process of obtaining consent posed significant risk of
influencing physician behaviour. This was deemed accept-
able, as selection of VTE prophylaxis was based on stan-
dard care and not by the audit protocol.
We estimated that a total of 2,400 evaluable patients
would be required in the audit (1200, 400 medical, 400
surgical and 400 orthopaedic, in each audit cycle) to detect a
difference between an A1 (baseline) proportion of patients
treated to guidelines of 0.60 and an A2 proportion of
patients treated to guidelines of 0.70 (odds ratio = 1.556)
and to have a power of at least 80% (5%, two-sided sig-
nificance level). Data were summarised using descriptive
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statistics. The normal approximation method was used to
calculate 95% confidence intervals for all sites combined.
Logistic regression was used to evaluate the primary end
point as to whether the use of the electronic risk assessment
system improved the appropriate use of thromboprophy-
laxis at A2 versus A1 (standard care). Odds ratios for the
effect of the electronic risk assessment tool were adjusted
for the study design (site and patient specialty type) and for
risk status (high risk, not high risk), as appropriate. All
statistical analyses were performed using SAS Version
9.2.
Results
A total of 2,406 patients were audited in this study, 1,206
in Audit 1 (A1), 402 medical, 404 surgical and 400
orthopaedic and 1,200 patients in Audit 2 (A2), 401 med-
ical, 398 surgical and 401 orthopaedic. Demographic data
for the patients audited are summarised in Table 1. Patients
were well matched for all demographic measures between
the two audits, as well as within each patient specialty type.
In A1, 947 (78.5%) patients were high risk at admission
and a similar percentage 78.7% (944) were high risk in A2.
As expected, high risk patients were older (mean age
67.8 years, A1 and 66.0 years, A2) compared to not high
risk patients (mean ages 49.1 years, A1 and 54.5 years,
A2).
The VTE risk factors found in patients are shown in
Table 2. Orthopaedic patients generally had fewer risk
factors however there was a considerable difference in A1
compared to A2 (no risk factors in 76.5% vs. 52.4%,
P \ 0.05). Differences were also observed in the preva-
lence of specific co-morbidities that increased VTE risk
between the two audits, for example active cancer was
more prevalent in A1 than A2, especially amongst medical
patients, while acute inflammation was more prevalent in
A2 than A1 amongst surgical and orthopaedic patients. The
number of VTE risk factors per patient is illustrated in
Fig. 1. The most common VTE risk factors reported in A1
were acute infection or acute inflammatory disorder
(31.7%, 382/1206) and active cancer (10.8%, 130/1206).
These risk factors were also the most common in A2
(Table 2). In both audits, only a minority of patients had a
risk factor for bleeding at admission (A1, 9.5% 114/1206
and A2, 5.8% 69/1200). The most common bleeding risk
was hepatic impairment (Table 2). Almost 20% of patients
had a contraindication to adding thromboprophylaxis in the
audit (A1, 19.0% 229/1206, and A2, 16.0% 192/1200). The
most common contraindications for initiating thrombo-
prophylaxis included high risk of bleeding, active bleeding
and range of other contraindications such as, renal
impairment, chronic kidney disease, palliative care and
falls risk. Seventy-two patients in A1 and 60 patients in A2
were already taking thromboprophylaxis at admission
(Table 2).
In A1, 66.8% (806/1206) of all patients and 63.5% (601/
947) of high risk patients were treated to guidelines. This
increased by 5.0% to 71.8% (862/1200) of all patients
(P \ 0.05) and by 10.7% to 74.2% (700/944) for high risk
patients (P \ 0.05) (Fig. 2a, b). The adjusted odds ratio
(AOR) of being treated to guidelines as a result of partic-
ipating in the audit increased significantly by 1.27 (95% CI
1.07–1.49), indicating that patients in A2 had a 1.27 times
higher odds, adjusted for risk status, of receiving appro-
priate VTE prophylaxis than from standard care, in A1.
Similarly the AORs of being treated to guidelines for high
risk patients was 1.65 (95% CI 1.37–1.99, P \ 0.05).
The use of the electronic risk assessment tool in A2 to
assess VTE risk varied between the participating centres,
ranging from none to half of the patients assessed using this
tool. Overall elVis was used in 22.6% (213/944) of high
Table 1 Patient demographics
Medical Surgical Orthopaedic Total
Audit 1
(n = 402)
Audit 2
(n = 401)
Audit 1
(n = 404)
Audit 2
(n = 398)
Audit 1
(n = 400)
Audit 2
(n = 401)
Audit 1
(n = 1206)
Audit 2
(n = 1200)
Male (%) 213 (53.0%) 198 (49.4%) 225 (55.7%) 220 (55.3%) 183 (45.8%) 191 (47.6%) 621 (51.5%) 609 (50.8%)
Female (%) 189 (47.0%) 203 (50.6%) 178 (44.1%) 178 (44.7%) 217 (54.3%) 210 (52.4%) 584 (48.4%) 591 (49.3%)
Mean age years (SD) 71.1 (17.7) 73.7 (16.2) 58.2 (20.2) 56.6 (20.3) 62.1 (19.4) 60.2 (19.7) 63.8 (19.9) 63.5 (20.2)
Mean weight kg (SD) 71.5 (21.4)
(n = 97)
71.4 (21.8)
(n = 121)
78.9 (19.8)
(n = 250)
78.2 (19.5)
(n = 219)
82.7 (19.7)
(n = 219)
82.0 (19.8)
(n = 238)
79.1 (20.4)
(n = 566)
78.3 (20.5)
(n = 578)
Mean height cm (SD) 169.0 (10.0)
(n = 13)
165.3 (9.0)
(n = 15)
167.6 (11.2)
(n = 144)
167.5 (10.7)
(n = 130)
167.0 (11.3)
(n = 149)
166.7 (11.6)
(n = 193)
167.3 (11.2)
(n = 306)
166.9 (11.1)
(n = 338)
Mean BMI kg/m2 (SD) 20.7 (6.8)
(n = 10)
22.1 (5.6)
(n = 14)
27.9 (7.4)
(n = 142)
27.7 (5.7)
(n = 130)
30.4 (6.6)
(n = 145)
30.2 (7.9)
(n = 190)
28.9 (7.3)
(n = 297)
28.9 (7.3)
(n = 334)
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risk patients and 20.5% (246/1,200) of all patients. Its use
also differed between specialty types, with highest use
amongst medical patients 35.2% (141/401), followed by
surgical patients, 17.8% (71/398) and orthopaedic patients,
8.5% (34/401). Due to the low use of the electronic risk
assessment tool, an additional logistic regression analysis
was conducted to determine its impact amongst patients in
audit 2 only. Seventy-eight percent (192/246) of patients
assessed using the electronic risk assessment tool received
appropriate prophylaxis versus 70.2% (670/954) for those
whose risk was assessed using another method. Adjusting
for risk status, patients assessed with electronic risk
assessment had 1.44 times greater odds of receiving
appropriate VTE prophylaxis than patients who were not
assessed using this system (AOR 1.44, 95% CI 1.04, 1.99).
Statistically significant improvements in the percentage of
all patients treated to guidelines were observed in A2 for
both medical patients and orthopaedic patients (AOR 1.56
and 1.36 respectively) but not for surgical patients
(Fig. 3a). Similar findings were observed amongst high risk
patients; however the study was not powered to detect
significant differences in this subanalysis (Fig. 3b).
Fig. 1 Number of VTE risk factors per patient (all patients)
Fig. 2 Percentage of patients treated to guidelines. a All patients. b High risk patients
Fig. 3 Percentage of patients treated to guidelines by specialty group. a All patients. b High risk patients
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The types of VTE prophylaxis prescribed in both audits
are shown in Table 3. The level of VTE risk and bleeding
risk differed between A1 and A2 and this influenced the
use of VTE prophylaxis. The percentage of patients overall
receiving any VTE prophylaxis in A2 compared to baseline
(A1) increased by 2.8% (not statistically significant), with a
statistically significant increase observed for the use of the
combination of anti-coagulant and mechanical prophylaxis.
The most frequently prescribed anticoagulant prophy-
laxis in all patients was enoxaparin (42.9% in A1 and
46.4% in A2), followed by unfractionated heparin and
dalteparin. The prescribing of enoxaparin increased in A2
amongst both medical and surgical patients, but decreased
amongst orthopaedic patients. Unfractionated heparin pre-
scribing decreased amongst surgical patients but increased
amongst medical patients. Dalteparin was only used
amongst orthopaedic patients. The most frequently pre-
scribed mechanical prophylaxis in patients overall was
graduated compression stockings.
Discussion
The routine use of VTE prophylaxis in hospitalised patients
is generally suboptimal, with the percentage of at risk
patients who receive prophylaxis according to guidelines
ranging from 13 to 64%, depending on the patient popu-
lation being investigated [23–26]. Data from the multi-
national ENDORSE study demonstrated that less than half
of patients at risk received prophylaxis and prophylaxis
was generally higher amongst surgical patients than med-
ical patients (58.5% surgical and 39.5% medical) [9]. The
hospitals that participated in our study performed VTE
prophylaxis at a relatively high rate in A1, prior to the
intervention, with approximately two-thirds of both, all
patients and high risk patients receiving appropriate
prophylaxis in A1. Despite these high baseline levels
implementing the electronic risk assessment tool and the
accompanying education activities resulted in further
improvements in VTE prophylaxis, increasing by 5.0% for
all patients and 10.7% for patients at high risk. This finding
is consistent with that of other investigators that confirm
that implementing active strategies that remind clinicians
to assess VTE risk and assist with appropriate prescribing
are effective [21, 27, 28]. For example, Durieux et al.
investigated the use of a computer-based clinical decision
support system on VTE prophylaxis amongst orthopaedic
patients. Use of the computerised system further improved
the percentage of patients treated to guidelines by 12.1%,
from 82.8 to 94.9% [28].
Our study also investigated VTE prophylaxis amongst
three discrete patient specialty types, medical, surgical and
orthopaedic patients, in equal proportions. Previous studiesT
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have indicated that VTE prophylaxis is generally imple-
mented better amongst surgical patients than medical
patients [9]. Although a higher percentage of surgical
patients received appropriate prophylaxis (72.8%) in A1,
the rate of prophylaxis according to guidelines amongst
medical patients was also high at 67.4% and higher than
orthopaedic patients at 60.3%. Improvement in VTE pro-
phylaxis was greatest amongst medical patients (8.9%
amongst all medical patients and 18.6% amongst high risk
medical patients). Significant improvements were also
observed amongst orthopaedic patients, whilst no signifi-
cant change was observed amongst surgical patients. These
differences between patient specialty type are partially
explained by the differing use of the electronic risk
assessment tool, which was most frequently used with
medical patients.
There was marked heterogeneity between the audited
hospitals and within patient specialty types. Hospitals and
specialty subgroups with the highest percentage of appro-
priate prophylaxis use in A1 ([80%) generally demonstrated
little change (marginal improvement) in VTE prophylaxis as
a result of participation in the audit. Amongst the remaining
hospitals three demonstrated improvements in VTE pro-
phylaxis, whilst in one hospital the intervention appeared to
impede appropriate prophylaxis.
The main limitation of our study resulted from the low
and variable use of the electronic risk assessment tool,
ranging from one hospital not assessing any patients with
the tool to its use to assess two-thirds of all medical
patients in another hospital. This variation arose from
several factors of which the two most significant were
software related issues and clinical leadership. In the pilot
study conducted at Geelong Hospital, the electronic risk
assessment tool was fully integrated within the hospital
admission system [29]. Hence, the risk assessment tool
formed a seamless part of the admission system. For all the
hospitals in our study, elVis was not fully integrated within
the hospital’s patient admission system but was a separate,
stand alone application. This created a major impediment
to its routine use, as clinicians needed to specifically open
the electronic risk assessment tool to assess VTE risk. In
addition, the routine use of the electronic risk assessment
system was further compromised by implementation issues
that arose at some hospitals, where synchronisation of
patient lists between the hospital admissions system and
the VTE risk assessment tool was not always achieved with
100% accuracy. When patients were missing from the VTE
database, VTE risk assessment defaulted to standard care.
The importance of clinical leadership was clearly demon-
strated from within hospital comparisons between patient
specialty types. Where clinical leadership was strong and
supportive of electronic risk assessment, usually in medical
departments, so was the use of the tool. Although patients
in each audit were well matched based on demographic
variables, differences in risk factors were observed. Whilst
adjustments have been made for measured confounders, it
is not possible to account for unmeasured confounders and
their potential impact on our results. Other limitations of
our study are the multiple statistical analyses conducted
increasing the chance of false positive results, the lack of
clarity as to the effect of elVis over education and whether
these improvements in VTE prophylaxis are sustainable.
Despite the varied use of elVis, analysis of patients
within the second audit identified a clinical benefit asso-
ciated with the use of this tool. Patients assessed using the
electronic risk assessment had 1.44 times higher odds,
adjusted for risk status, to receive appropriate VTE pro-
phylaxis than patients who were not assessed using this
system (P \ 0.05).
The most significant challenge in the area of VTE pro-
phylaxis is the application of existing evidence into
everyday clinical practice. Quality improvement and prac-
tice change is possible but for it to be sustained it requires
that the change be integrated into daily patient care [21, 30,
31]. The use of computerised risk assessment and reminder
systems make this possible and has been demonstrated to be
effective tools of change in the area of preventative care
[27–30]. For example, a randomised clinical trial in 2,506
hospitalised patients demonstrated that the use of comput-
erised alert system increased physician use of VTE
prophylaxis versus control (33.5% vs. 14.5%, P \ 0.001)
and reduced the risk of DVT or PE at 90 days by 41%
(P = 0.001) [27]. In addition, a systematic review by
Tooher et al. [21], found that computer based clinical
decision support systems were amongst the most effective
strategies for improving prescribing practice as they mini-
mise errors made by clinicians with varying degrees of
knowledge, interest and motivation for VTE prevention.
This review also identified that the studies that achieved at
least 90% adherence to VTE guidelines involved either an
iterative process of audit and review or an active reminder
system.
In our study, the absolute improvement in the percent-
age of patients that were treated to guidelines was 5.0%
amongst all patients and 10.7% amongst high risk patients
as a result of the audit intervention. The audit intervention,
although focused on the use of the electronic risk assess-
ment tool was effectively a multimodal intervention,
involving clinical leadership, professional education,
increased awareness of VTE prophylaxis, as well as the use
of the elVis electronic risk assessment tool. The absolute
improvement in appropriate VTE prophylaxis increased by
7.8% amongst patients who were assessed using the elec-
tronic risk assessment compared to not using this tool. This
level of absolute improvement in clinical practice is com-
parable to other change management tools aimed at
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improving guideline implementation. Grimshaw et al. [32]
identified that reminder systems were the most effective
tool for change (median absolute effect of 13.1%), fol-
lowed by healthcare professional education at 8.1% (noting
that the benefits from this tool of change is short-lived),
audit and feedback 7.0% and multifaceted interventions
involving educational outreach at 6.0%.
Conclusion
The use of elVis, an electronic VTE risk assessment tool,
accompanied by staff education overall improved VTE
prophylaxis, especially amongst high risk patients. How-
ever, the response to this intervention varied between
participating hospitals and between medical, surgical and
orthopaedic patients. Our study confirmed that the ongoing
challenge of applying VTE prophylaxis guidelines into
routine clinical practice can be assisted with the use of
electronic assessment and decision support tools. To be
maximally effective and to deliver enduring practice
change, these tools need to be fully integrated within the
treatment pathway in a readily accessible, easy to use
manner.
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